← Browse by Condition
Medical Condition

immunotherapy

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for immunotherapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — immunotherapy Clinical Trials

How many clinical trials are currently recruiting for immunotherapy?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for immunotherapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for immunotherapy?
immunotherapy research spans Phase 1 (1 trial), Phase 2 (5 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a immunotherapy clinical trial?
Eligibility criteria for immunotherapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
5
Phase 3
1
Top Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 4 trials
Seventh Medical Center of PLA General Hospital 1 trial
Guangdong Association of Clinical Trials 1 trial
West China Hospital 1 trial
University Hospital Southampton NHS Foundation Trust 1 trial

Recruiting Clinical Trials

NCT06429839 Phase 2
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Enrollment
55 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT07458529 Phase 2
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Enrollment
50 pts
Location
China
Sponsor
Seventh Medical Center of PLA ...
View Trial →
NCT04286841
Recruiting
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
Enrollment
100 pts
Location
China
Sponsor
Guangdong Association of Clini...
View Trial →
NCT06421376 Phase 2
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Enrollment
60 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT04821843 Phase 3
Recruiting
Neoadjuvant Treatment Modalities in Esophageal Cancer
Enrollment
2,000 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT07072351 Phase 1, Phase 2
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
Enrollment
88 pts
Location
China
Sponsor
West China Hospital
View Trial →
NCT07668037
Recruiting
Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
Enrollment
600 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT07354971
Recruiting
IMMUNO-FIT Observational Study
Enrollment
67 pts
Location
United Kingdom
Sponsor
University Hospital Southampto...
View Trial →
NCT07669220 Phase 2
Recruiting
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
Enrollment
76 pts
Location
China
Sponsor
Sixth Affiliated Hospital, Sun...
View Trial →

Related Conditions

esophageal cancer (3) chemoradiotherapy (2) chemotherapy (2) surgery (2) nimotuzumab (1) rectal cancer adenocarcinoma (1) neoadjuvant therapy (1) probio m9 (1) tislelizumab (1) randomized (1) lung cancer (1) induction therapy (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology